NYSE: BIOA STOCK INFORMATION
Select from the drop-down menu below to view the latest trading information on our common stock and warrants, which are both traded on the New York Stock Exchange (NYSE:BIOA and NYSE:BIOA.WS respectively).
Back to Top
|John Quealy / Chip Moore||Canaccord Genuity||+1 (617) 371-3837/3879|
|Alex Stewart||Barclays||+44 (0) 7880 093219|
|Peter Clark||Société Générale||+44 20 7762 5084|
|Amit Dayal||Rodman & Renshaw||+1 (212) 356-0517|
|Dirk Lever||AltaCorp.||+1 (403) 539-8606|
LEADERSHIP & GOVERNANCE
LEADERSHIP & GOVERNANCE
BioAmber has assembled a team of industry veterans in the fields of industrial biotechnology and chemicals. Having assembled unmatched experience and unrivalled technical and business acumen, BioAmber is positioned to lead the emergence of economically-viable, sustainable chemicals. The company has staffed its board of directors and management team with seasoned professionals possessing strong track records and complementary experience.
The management team is to promote sustainable development, ownership of issues, proper behavior, and innovative technology, all of which foster eco efficiency and a safe working environment. We are firmly committed to the pursuit of HSE excellence – not just for today but for the future.
The Company’s Board of Directors has established an Audit Committee, a Compensation Committee and a Nominating and Corporate Governance Committee, each of which operates pursuant to a charter adopted by our board of directors.
Below is a summary of our committee structure and membership information. To read more about any of the committees, click on committee names in the chart below.
|Audit Committee||Compensation Committee||Nominating and Corporate Governance Committee|
|Raymond J. Land|
|George F.J. Gosbee|
|Ellen B. Richstone|
|Kenneth W. Wall|
Raymond J. LandChairman
Raymond Land joins BioAmber as an independent board member and Chair of the audit committee. Ray has over 35 years financial experience and has been the Chief Financial Officer of four publicly traded companies: Clarient (CLRT), Orchid Cellmark (ORCH), Genencor (GCOR) and West Pharmaceutical Services (WST). He was formerly the Vice President-Corporate Controller and then a Vice–President General Manager of Campbell Soup Co.’s Frozen Food Division. Ray has also been the audit committee chair for several private and public companies. Ray has extensive experience in assisting start-ups put in place the financial organizations, systems and procedures needed to manage rapid growth and ensure compliance. Ray is a certified public accountant and spent 9 years at Coopers & Lybrand.
Kurt Briner is an independent consultant to pharmaceutical and biotechnology companies. He has over 30 years of experience in the pharmaceutical industry. Mr Briner is the former President and Chief Executive Officer of Sanofi Pharma S.A. in Paris, France, a position he held from 1988 until his retirement in 2000.
Mr. Briner was a director of Novo Nordisk and Galenica S.A. (Switzerland) and is an active Board member of Progenics Pharmaceuticals Inc. (USA) Mr. Briner holds a Diploma of the Commercial Schools of Basel and Lausanne, Switzerland.
Heinz Haller joins BioAmber as an independent board member with over 25 years of experience in the chemical industry. Heinz is Executive Vice President of The Dow Chemical Company, and President of Dow Europe, Middle East, Africa and India. He is also the chairman of the board of Dow Kokam, a lithium ion battery JV with Townsend Ventures. He also sits on the board of Advanced Electrolytes, a JV between Dow and Ube Industries of Japan and serves on the board of Dow Corning, a JV between Dow and Corning, as the lead director for Dow. Heinz is a member of Dow’s Executive Leadership Committee and co?chairs the Growth and Innovation Team with the CTO of Dow. Prior to his present responsibilities he was responsible for the Performance Materials Division of DOW. Heinz is a former CEO of OMYA/Pluess-?Stauffer, a privately held company active in chemical distribution and the world’s largest calcium carbonate mining company. Heinz is a former CEO of Red Bull Sauber AG and Sauber Petronas Engineering AG, and a former Managing Director of Allianz Capital Partners GmbH.
Prior to BioAmber, Jean-François Huc was the Chief Operating Officer of Diversified Natural Products (DNP), where oversaw the spin off of the succinic acid assets, at which time he stepped down from DNP to become President and CEO of BioAmber. Prior to DNP Mr. Huc was CEO of TGN Biotech, a company producing recombinant proteins in transgenic animals. Prior to TGN, he was the founder and CEO of MedExact, a startup offering web-based promotional services to pharmaceutical companies in the US and France. Mr. Huc is a former Vice President of Alliance Management for Sanofi-Synthelabo, based in Paris, where he managed the company's global strategic alliances. Prior to Sanofi, he was a Partner with Arthur D. Little, a management consulting firm and Director of its French healthcare practice. Mr. Huc has an M.B.A. from York University in Toronto and an undergraduate degree in biochemistry from the University of Western Ontario.
Ellen B. RichstoneExecutive
Ms. Richstone was the Chief Financial Officer of several public and private companies between 1989 and 2012, including Rohr Aerospace (a Fortune 500 Company). From 2002 to 2004, Ms. Richstone was the President and Chief Executive Officer of the Entrepreneurial Resources Group. From 2004 until its sale in 2007, Ms. Richstone served as the financial expert on the board of directors of American Power Conversion. Ms. Richstone currently serves on the boards of three public companies: Bioamber, eMagin (NYSE: EMAN); Everyware Global (NASDAQ: EVRY) and on the boards of both private corporations and non profits including the National Association of Corporate Directors-New England. She chairs the Audit Committees of both eMagin and Everyware Global. In April 2013, Ms. Richstone was given the first annual Distinguished Director Award from the Corporate Directors Group. Ms. Richstone graduated from Scripps College in Claremont California and holds graduate degrees from the Fletcher School of Law and Diplomacy at Tufts University. Ms. Richstone also completed the Advanced Professional Certificate in Finance at New York University’s Graduate School of Business Administration and attended the Executive Development program at Cornell University’s Business School. Ms. Richstone holds an Executive Master’s Certification in Director Governance from the American College of Corporate Directors. We believe that Ms. Richstone’s broad industry experience in technology, industrial and cleantech, as well as her financial and corporate governance expertise will make her a valuable member of our board of directors.
Kenneth W. Wall
George F.J. Gosbee
Mr. Gosbee's career spans over 20 years in corporate finance, investment banking, global capital markets and advisory. Prior to founding AltaCorp Capital in 2010, Mr. Gosbee was Chairman, President and CEO of Tristone Capital Global Inc., a global energy investment firm which he founded. Tristone became the largest global independent energy advisory firm and was acquired by an international bank in 2009. His current firm, AltaCorp Capital, is an advisory firm that is partnered with Alberta Treasury Branch (ATB Financial), a wholly owned subsidiary of the Government of Alberta.
Mr. Gosbee is a former Governor of the National Hockey League (NHL). He led a group to purchase the Arizona Coyotes and restructure the Club. Currently he is an Alternate Governor on the NHL Board of Governors and Co-owner of the Arizona Coyotes.
Mr. Gosbee was the Vice Chairman of Alberta Investment Management Co (AIMCo) and was called on to assist in the creation of the crown corporation. He spent 8 years as the Vice Chair of AIMCo, which is a $90 billion institutional investment fund, and currently is a Director. Mr. Gosbee is a former Director of the TMX Group and a former Board Member of Chrysler Group LLC in Detroit, where he served on behalf of both the Canadian Federal and Provincial (Ontario) governments to oversee their collective investment in the company and assist in the restructuring.
Fabrice OrecchioniPresident & COOFabrice Orecchioni is BioAmber’s Chief Operations Officer. In his role, he oversees engineering, procurement and construction activities (EPC), as well as overall operations, including manufacturing and supply chain. Fabrice joined BioAmber in January 2012 and served as Plant Manager and Sr VP, Operations. Prior to BioAmber, Mr. Orecchioni was Plant Manager at Abengoa Bioenergy where he was in charge of the start-up and operation of Abengoa's French BioFuel Facility during 5 years. Fabrice also spent 10 years in Amino Acids Fermentation business at Tate & Lyle and Ajinomoto Foods Europe through various positions around Process and Operations management. Mr. Orecchioni holds an Executive Master of Business Administration from HEC Paris, a degree in Bio-Process Engineering from École de Biologie Industrielle, and a degree in Chemistry from Université Pierre-et-Marie-Curie.
R. Laurent BernierSenior VPUntil the recent spin-off of BioAmber Inc. from Diversified Natural Products, Laurent BERNIER was Vice President R&D working on the restructuring of DNP’s succinic acid division more particularly on the management of its IP portfolio and various scientific and business partnerships. Prior to joining BioAmber and Diversified Natural Products, Dr. BERNIER was Vice President Eastern Canada for Foragen Technology Management Inc., a venture capital fund created to help commercialize early-stage, advanced agricultural technologies from Canadian sources. Before Foragen, he was the founding Executive Director of BioNB (formerly known as BioAtlantech), New-Brunswick’s lead agency for the development of the bio-industries and had been previously Vice President Life Sciences for Inno-centre, a Montreal-based organization dedicated to helping advanced technology entrepreneurs start up commercial ventures. As an industrial researcher, Laurent BERNIER has held various research and managerial positions at C-I-L, ICI Canada and Zeneca BioProducts, where he directly contributed to the discovery, development and launch of five biotechnology-related products and services. He is listed as an inventor of a dozen biotechnology related patents and has published extensively in the area of agricultural and forestry biotechnology. Dr. Bernier has held various adjunct professorships and has been a guest lecturer at several Canadian universities. He received his Ph.D. in Microbiology and Immunology from the University of Montreal. He was a recipient of an INSERC industrial post-doctoral fellowship conducted at FPInnnovations (formerly the Pulp and Paper Research Institute of Canada or PAPRICAN) in collaboration with McGill University in Montreal. He is currently Chairman of the Board of CRIBIQ (QC) and AIREX Énergie inc.
Thomas DesbiensGeneral Counsel
Thomas Desbiens is a business and intellectual property lawyer with more than twenty years of experience as partner in a boutique law firm, who oversees BioAmber’s legal matters, including its corporate & commercial transactions, financing activities, strategic partnerships and securities compliance & corporate governance matters.
He has extensive national and international expertise in assisting fast growing companies involved in complex technological environments, and representing numerous companies in connection with venture capital & debt financings, initial public offerings, merger & acquisition transactions, strategic alliances, commercial & licensing agreements and corporate governance matters.
Mike HartmannExecutive VPMike Hartmann was previously responsible for the institutional sales and trading desk for CIBC World Markets in Montreal. His ten year career started in sales with CIBC WM and was promoted to Executive Director and oversaw the institutional equity sales and trading desk. He helped initiate and was the co-chairman of one of Canada's premier institutional conference for seven years. During his time at CIBC WM, over a billion dollars in equity was raised through IPOs, secondary offerings and bought deals for the Montreal office that was part of billions raised in equity over his career at CIBC WM. Prior to that, he was an institutional sales representative with Sprott Securities that specialized in small cap, fast growing companies. Mr. Hartmann is the Treasurer of the Canadian Andover Fund, providing scholarships to qualified students in Canada to attend Andover prep school in Andover MA. He has an International MBA from York University and received his BA from Rollins College in FL with a major in Economics.
Mario SaucierCFOMario Saucier joined BioAmber as Chief Financial Officer in January 2016. He comes to us as a skilled financial executive with extensive on-point skills as well as strong leadership and financial insight in large and medium international publicly traded companies. In his role as CFO, Mr. Saucier’s focus will be in overseeing the financial function of the company including treasury, budget planning, investor relations and information systems.
He carries over 20 years of experience in senior financial and operational positions including his most recent role from May 2014 until November 2015 as CFO of Norduyn. While serving as CFO, Mr. Saucier also acted as President for Transtex Composite, a subdivision of Norduyn.
Prior to Norduyn, he served as CFO at Englobe Corp., a bio-remediation Company where he accomplished the restructuring and refinancing of the firm as well as attained the mandate of privatising the company, all within a 24 month period. This achievement brought him to be appointed as interim Chief Executive Officer for a six month period with Englobe Corp. Previous positions also include Senior Vice President of Finance and Chief Accounting Officer of Quebecor World, Vice President Strategy & Performance of Total Transit System, a division of Bombardier Transportation, as well as Vice President Implementation SAP leading the largest SAP project in Canada.
Mr. Saucier holds a B.B.A. from the Université du Québec à Montréal and has been a member of the Canadian Institute of Chartered Accountants since 1991.
James MillisCTOJames Millis, CTO, has worked in the field of industrial biotechnology for 30 years. Mr. Millis most recently served as CEO of Draths Corporation. His prior appointment was as Technical Director for Cargill's Industrial Bioproducts business unit, during which time new chemical businesses were created in biobased urethane polyols and in the application of metathesis chemistry, the latter now Elevance. Earlier positions included business and technical leadership roles at Maxygen and Bio-Technical Resources. Mr. Millis has been involved in the commercial development and scale-up of several technologies, spanning fermentation and chemical catalysis, and is co-inventor on 12 US patents and their foreign equivalents.
Feb 20, 2017
BioAmber Inc. (NYSE: BIOA) announced today that Jean-Francois Huc has resigned as President and CEO and Fabrice Orecchioni, the company's COO, has been named President, effective immediately. In...More
Jan 30, 2017
BioAmber Inc. (NYSE: BIOA) is pleased to announce that on January 27th the Company reimbursed its CDN$25 million loan (approximately US$19.3 million) with Bridging Finance Inc. Following the...More
Jan 24, 2017
BioAmber Inc. (NYSE: BIOA) announced that, due to strong demand, the underwriters have agreed to increase the size of the offering by 75% and purchase 3,684,212 shares of common stock of the...More